2 Information about sofosbuvir–velpatasvir–voxilaprevir
|
Marketing authorisation indication |
Sofosbuvir–velpatasvir–voxilaprevir (Vosevi, Gilead Sciences) has a marketing authorisation in the UK for 'the treatment of chronic hepatitis C virus infection in adults'. This includes genotypes 1–6, with or without compensated cirrhosis, and includes people who have had previous treatment with direct-acting antivirals. |
|---|---|
|
Dosage in the marketing authorisation |
The recommended dose is 1 tablet taken orally once daily. Each tablet contains 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir. Treatment duration is 8 or 12 weeks depending on cirrhosis status and whether the person has had previous treatment with direct-acting antivirals. Please see the summary of product characteristics for more details. |
|
Price |
Sofosbuvir–velpatasvir–voxilaprevir costs £14,942.33 per 28‑day pack. The total costs are £29,884.66 for an 8-week course and £44,826.99 for a 12-week course (company submission). The company agreed a nationally available price reduction for sofosbuvir–velpatasvir–voxilaprevir with the Commercial Medicines Unit. The contract prices agreed through the framework are commercial in confidence. |